I describe how biomarkers such as BNP and NT-proBNP can help influence decisions about the diagnosis and prognosis of heart failure.
In this CME-certified video module, Keith C. Ferdinand, MD, FACC, FAHA, discusses approaches to recognizing patients with elevated HF risk, using biomarkers to support HF diagnosis and prognosis, and integrating the latest treatment options into evidence-based management therapies, with a focus on treating special patient populations.
A paucity of randomized data has led to a wide range of clinical practices regarding the delivery and dosing of loop diuretics in patients with acute heart failure. Here’s my approach.
In this downloadable slideset, G. Michael Felker, MD, MHS, FACC, FAHA, and Javed Butler, MD, MPH, MBA, discuss recent data concerning the diagnosis and management of acute heart failure, including the use of biomarkers in diagnosis and prognosis, benefits and limitations of current standards of care, and evidence regarding investigational therapeutics.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.